NRIX:NSD-Nurix Therapeutics Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 24.8

Change

+1.23 (+5.22)%

Market Cap

USD 1.57B

Volume

0.40M

Analyst Target

USD 36.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-13 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

-6.33 (-0.55%)

USD 127.14B
VRTX Vertex Pharmaceuticals Inc

-8.17 (-1.67%)

USD 125.27B
ALNY Alnylam Pharmaceuticals Inc

+4.09 (+1.51%)

USD 34.71B
ARGX argenx NV ADR

-15.72 (-2.92%)

USD 32.33B
MRNA Moderna Inc

+2.82 (+4.08%)

USD 26.25B
SMMT Summit Therapeutics PLC

-3.26 (-11.06%)

USD 23.47B
BGNE BeiGene Ltd

+1.06 (+0.54%)

USD 21.94B
RPRX Royalty Pharma Plc

-0.02 (-0.07%)

USD 16.45B
BMRN Biomarin Pharmaceutical Inc

+0.69 (+0.99%)

USD 16.16B
UTHR United Therapeutics Corporatio..

+0.04 (+0.01%)

USD 15.09B

ETFs Containing NRIX

IDNA iShares Genomics Immunolo.. 1,000.00 % 0.00 %

+0.06 (+3.73%)

USD 0.14B
ARKG 4.06 % 0.75 %

N/A

N/A
ARKG:LSE ARK Genomic Revolution UC.. 4.05 % 0.00 %

+0.18 (+3.73%)

USD 2.92M
ARCG:LSE ARK Genomic Revolution UC.. 3.95 % 0.00 %

+14.68 (+3.73%)

USD 2.92M
CNCR Loncar Cancer Immunothera.. 2.34 % 0.79 %

-0.20 (3.73%)

USD 0.01B
BBC Virtus LifeSci Biotech Cl.. 1.16 % 0.79 %

-0.21 (3.73%)

USD 0.01B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 140.31% 94% A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 140.31% 94% A 96% N/A
Trailing 12 Months  
Capital Gain 179.91% 94% A 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 179.91% 94% A 97% N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -9.74% 43% F 26% F
Dividend Return -9.74% 43% F 25% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 50.29% 63% D 36% F
Risk Adjusted Return -19.38% 40% F 29% F
Market Capitalization 1.57B 85% B 76% C+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector